Skandinaviska Enskilda Banken (SEB)’s BridgeBio Pharma BBIO Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-237,791	Closed	-$18.2M	–	223
2025 Q4	$18.2M	Buy	237,791 +88,874	+60%	+$5.83M	0.07%	188
2025 Q3	$7.73M	Buy	148,917 +89,856	+152%	+$4.38M	0.03%	330
2025 Q2	$2.55M	Hold	59,061	–	–	0.01%	540
2025 Q1	$2.04M	Buy	59,061 +17,547	+42%	+$592K	0.01%	573
2024 Q4	$1.13M	Buy	41,514 +11,325	+38%	+$293K	0.01%	645
2024 Q3	$769K	Hold	30,189	–	–	﹤0.01%	689
2024 Q2	$765K	Hold	30,189	–	–	﹤0.01%	658
2024 Q1	$933K	Hold	30,189	–	–	﹤0.01%	663
2023 Q4	$1.22M	Hold	30,189	–	–	0.01%	669
2023 Q3	$796K	Buy	+30,189	New	+$857K	0.01%	711
2020 Q3	–	Sell	-16,700	Closed	-$545K	–	1034
2020 Q2	$545K	Buy	+16,700	New	+$509K	﹤0.01%	800

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s BBIO Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 237,791 shares — an estimated $18.2M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in BBIO in Q2 2020 and held it in 11 quarters. The position peaked at $18.2M in Q4 2025. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Skandinaviska Enskilda Banken (SEB) reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 237,791 BridgeBio Pharma shares in Q1 2026, an estimated $18.2M.
Skandinaviska Enskilda Banken (SEB) first reported a position in BridgeBio Pharma in Q2 2020 and held it in 11 quarters.
Skandinaviska Enskilda Banken (SEB)'s BridgeBio Pharma position peaked at $18.2M in Q4 2025.
460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.